Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abiprubart in Sjögren's Disease
NCT06531395Phase 2Terminated
- Sponsor
- Kiniksa Pharmaceuticals
- Start
- Jul 2024
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of Abiprubart in Sjögren's syndrome, sponsored by Kiniksa Pharmaceuticals. Started Jul 2024; status: terminated.
02
Drugs
Abiprubart
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on NCT06531395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06531395.